Sebastiano Battaglia, MD Sebastiano Battaglia, MD

Sebastiano Battaglia


Special Interests:

Immunotherapy Bioinformatics/immunogenomics Immunology Prostate cancer Ovarian cancer

About Sebastiano Battaglia


Cancer Talk Blog


Roswell Park Comprehensive Cancer Center

  • Assistant Professor of Oncology
  • Department of Immunology


Education and Training:

  • 2015 - MS - Bioinformatics - Johns Hopkins University, Baltimore, MD
  • 2010 - PhD - Cancer Biology - University of Birmingham, Birmingham, England, UK
  • 2005 - MSc/BSc - Medical Biotechnology - University of Milan, Milan, Italy


  • 2016 - Post-Doctoral - Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Professional Memberships:

  • American Society for Human Genetics (ASHG)
  • American Association for Cancer Research (AACR)

Professional Experience:

  • 2010-Present - Roswell Park Comprehensive Cancer Center, Buffalo, NY
  • 2006-2009 - University of Birmingham, Birmingham, England, UK
  • 2008-2009 - Max Planck Institute For Molecular Genetics, Berlin, Germany
  • 2008 - University of Luxembourg
  • 2003-2005 - University of Milan/Istituto Nazionale dei Tumori, Milan, Italy


Research Overview:

Tumor cells present a mosaic of genetic mutations that can drive tumor development and progression. Mutations present only in tumor samples are called somatic mutations and can be exploited for immunotherapeutic interventions that utilize the patient’s own immune system to target and eliminate cancer cells. This mutational fingerprint is cancer-specific and allows for a clear distinction between normal and cancerous tissues. Thanks to this specificity, cancer vaccines are growing in popularity as potent therapeutic options in melanoma, kidney and ovarian cancer, to mention a few.

In order to successfully design a cancer vaccine, there is a strong need to identify reliable targets, or neoantigens, and for the neoantigens to be recognized by the T-cell receptor (TCR) on T-lymphocytes. My research focuses on integrating bioinformatics, immunological and genetic approaches to identify neoantigens and their corresponding TCRs in neoplastic tissues order to translate them into clinically usable cancer vaccines.

Featured on Cancer Talk


Full Publications list on PubMed
  • Verone-Boyle AR, Shoemaker S, Attwood K, Morrison CD, Makowski AJ, Battaglia S, Hershberger PA. Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. Oncotarget. 2016 Jan 5;7(1):995-1013. doi: 10.18632/oncotarget.6493. PMID: 26654942; PMCID: PMC4808047.
  • Doig CL, Battaglia S, Khanim FL, Bunce CM, Campbell MJ. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):47-55. doi: 10.1016/j.jsbmb.2015.09.037. Epub 2015 Sep 30. PMID: 26429394; PMCID: PMC5391256.
  • Long MD, van den Berg PR, Russell JL, Singh PK*, Battaglia S*, Campbell MJ*. Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. Nucleic Acids Res. 2015 Sep 3;43(15):7330-48. doi: 10.1093/nar/gkv642. Epub 2015 Jun 27. PMID: 26117541; PMCID: PMC4551916.
  • Battaglia S, Maguire O, Thorne JL, Hornung LB, Doig CL, Liu S, Sucheston LE, Bianchi A, Khanim FL, Gommersall LM, Coulter HS, Rakha S, Giddings I, O'Neill LP, Cooper CS, McCabe CJ, Bunce CM, Campbell MJ. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis. 2010 Sep;31(9):1650-60. doi: 10.1093/carcin/bgq086. Epub 2010 May 13. PMID: 20466759; PMCID: PMC2930800.
  • Battaglia S, Maguire O, Campbell MJ. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer. 2010 Jun 1;126(11):2511-9. doi: 10.1002/ijc.25181. Review. PMID: 20091860; PMCID: PMC2847647.

* Joint last authors